These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

838 related articles for article (PubMed ID: 32035355)

  • 21. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first complete remission after 5-azacitidine and venetoclax: a multicenter retrospective study.
    Pasvolsky O; Shimony S; Ram R; Shimoni A; Shargian L; Avni B; Wolach O; Shochat T; Yerushalmi R; Amit O; Raanani P; Yeshurun M
    Ann Hematol; 2022 Feb; 101(2):379-387. PubMed ID: 34628534
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study.
    Wei AH; Strickland SA; Hou JZ; Fiedler W; Lin TL; Walter RB; Enjeti A; Tiong IS; Savona M; Lee S; Chyla B; Popovic R; Salem AH; Agarwal S; Xu T; Fakouhi KM; Humerickhouse R; Hong WJ; Hayslip J; Roboz GJ
    J Clin Oncol; 2019 May; 37(15):1277-1284. PubMed ID: 30892988
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Clinical Observation of Venetoclax Combined with Demethylating Agents on the Treatment of Relapsed/Refractory Acute Myeloid Leukemia].
    Wang Y; Huang SL; Zhang XX; Bian MR; Lin GQ; Si YJ; Zhang B; Wan Y; Wang L; Zhang YM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Apr; 31(2):327-332. PubMed ID: 37096501
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Efficacy and safety of venetoclax combined with azacitidine versus CAG regimen combined with decitabine in elderly patients with relapsed acute myeloid leukemia].
    Wang P; Zhang LW; Lu CQ; Wang TZ; Shan M; Xiao JY; Tian H; Ma X; Xu Y; Wu DP
    Zhonghua Nei Ke Za Zhi; 2022 Feb; 61(2):157-163. PubMed ID: 35090250
    [No Abstract]   [Full Text] [Related]  

  • 25. Venetoclax-based chemotherapy in acute and chronic myeloid neoplasms: literature survey and practice points.
    Gangat N; Tefferi A
    Blood Cancer J; 2020 Nov; 10(11):122. PubMed ID: 33230098
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Homoharringtonine may help improve the outcomes of venetoclax and azacitidine in AML1-ETO positive acute myeloid leukemia.
    Yin Z; Yao Z; Chen D; Zhang Y; Weng G; Du X; Lin D; Xiao J; Sun Z; Zhang H; Liang X; Guo Z; Zhao W; Xuan L; Jiang X; Shi P; Liu Q; Ping B; Yu G
    J Cancer Res Clin Oncol; 2024 Jul; 150(7):336. PubMed ID: 38969948
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia.
    Aldoss I; Yang D; Aribi A; Ali H; Sandhu K; Al Malki MM; Mei M; Salhotra A; Khaled S; Nakamura R; Snyder D; O'Donnell M; Stein AS; Forman SJ; Marcucci G; Pullarkat V
    Haematologica; 2018 Sep; 103(9):e404-e407. PubMed ID: 29545346
    [No Abstract]   [Full Text] [Related]  

  • 28. Limited Efficacy of Venetoclax Combination Regimens in Acute Myeloid Leukemia with Extramedullary Relapse.
    Bae S; Sa S; Park S; Cho BS; Kim HJ
    Acta Haematol; 2024; 147(3):352-359. PubMed ID: 37751714
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.
    DiNardo CD; Pratz K; Pullarkat V; Jonas BA; Arellano M; Becker PS; Frankfurt O; Konopleva M; Wei AH; Kantarjian HM; Xu T; Hong WJ; Chyla B; Potluri J; Pollyea DA; Letai A
    Blood; 2019 Jan; 133(1):7-17. PubMed ID: 30361262
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcomes of relapsed or refractory acute myeloid leukemia patients failing venetoclax-based salvage therapies.
    Zucenka A; Pileckyte R; Trociukas I; Peceliunas V; Vaitekenaite V; Maneikis K; Davainis L; Zvirblis T; Stoskus M; Gineikiene E; Norvilas R; Dirse V; Surauciute A; Zucenkiene E; Griskevicius L
    Eur J Haematol; 2021 Jan; 106(1):105-113. PubMed ID: 32997830
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Venetoclax plus a hypomethylating agent versus cytarabine, aclarubicin, and granulocyte colony-stimulating factor chemotherapy as a first-line therapy for newly diagnosed acute myeloid leukemia: A propensity score-matched analysis.
    Huang R; He H; Xu X; Lin X; Dong Y; Wang X; Jiang F; Huang P; Mo S; Huang Z; Wang Y; Tao H; Zheng Y; Wu M; Yang C; Zheng Z; Zhao Y; Zhang Y; Li Y
    Cancer; 2024 Jul; 130(14):2472-2481. PubMed ID: 38470375
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients.
    Morsia E; McCullough K; Joshi M; Cook J; Alkhateeb HB; Al-Kali A; Begna K; Elliott M; Hogan W; Litzow M; Shah M; Pardanani A; Patnaik M; Tefferi A; Gangat N
    Am J Hematol; 2020 Dec; 95(12):1511-1521. PubMed ID: 32833294
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Real-world results of venetoclax combined with hypomethylating agents in young adults with relapsed/refractory acute myeloid leukemia.
    Xu X; Liu R; He A; Wang F
    Hematology; 2023 Dec; 28(1):2265206. PubMed ID: 37796109
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Venetoclax + hypomethylating agents combined with dose-adjusted HAG for relapsed/refractory acute myeloid leukemia: Two case reports.
    Wang H; Bai J; Pei Z; Zhang B; Wang J; Lian X; Song Q
    Medicine (Baltimore); 2020 Nov; 99(47):e23265. PubMed ID: 33217852
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Azacitidine-venetoclax versus azacitidine salvage treatment for primary induction failure or first relapsed acute myeloid leukaemia patients.
    Petit C; Saillard C; Mohty B; Hicheri Y; Villetard F; Maisano V; Charbonnier A; Rey J; D'Incan E; Rouzaud C; Gelsi-Boyer V; Murati A; Lhoumeau AC; Ittel A; Mozziconacci MJ; Alary AS; Hospital MA; Vey N; Garciaz S
    Eur J Haematol; 2024 Apr; 112(4):530-537. PubMed ID: 38031389
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Effect of venetoclax plus chemotherapy on treatment-naive acute myeloid leukemia patients with moderate to poor cytogenetic profiles and the combination's influence on the expression of proteins of the anti-apoptoic family].
    Zhonghua Zhong Liu Za Zhi; 2024 Feb; 46(2):161-167. PubMed ID: 38418191
    [No Abstract]   [Full Text] [Related]  

  • 37. Hypomethylating agents in combination with venetoclax for acute myeloid leukemia: Update on clinical trial data and practical considerations for use.
    Mei M; Aldoss I; Marcucci G; Pullarkat V
    Am J Hematol; 2019 Mar; 94(3):358-362. PubMed ID: 30499168
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cytogenetics and mutations could predict outcome in relapsed and refractory acute myeloid leukemia patients receiving BCL-2 inhibitor venetoclax.
    Wang YW; Tsai CH; Lin CC; Tien FM; Chen YW; Lin HY; Yao M; Lin YC; Lin CT; Cheng CL; Tang JL; Chou WC; Hou HA; Tien HF
    Ann Hematol; 2020 Mar; 99(3):501-511. PubMed ID: 31965269
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hypomethylating Agents and Venetoclax for Acute Myeloid Leukemia Relapsed After Hematopoietic Stem Cell Transplant.
    Ionescu F; David JC; Ravichandran A; Sallman DA; Sweet K; Komrokji RS; Chan O; Kuykendall A; Padron E; Faramand R; Bejanyan N; Khimani F; Elmariah H; Pidala J; Mishra A; Perez L; Nishihori T; Lancet JE
    Clin Lymphoma Myeloma Leuk; 2024 Jun; 24(6):400-406. PubMed ID: 38429222
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Venetoclax in Combination with Hypomethylating Agents for the Treatment of Treatment-Naive B/Myeloid Mixed-Phenotype Acute Leukemia and Relapsed/Refractory Acute Myeloid Leukemia: A Report of 3 Cases.
    Wang N; He J; Liu F
    Chemotherapy; 2022; 67(3):178-182. PubMed ID: 35306492
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 42.